Yigal Nochomovitz

Analysts: Galera Has Novel Pipeline For Radiation Oncology Market, Commercialization Remains Headwind

How Does Mirati's Lung Cancer Candidate Stack Up Against Amgen's?

5 Small-Cap Biotechs In Citi's Buy List With Big Upside Potential

How Does Mirati's Lung Cancer Candidate Stack Up Against Amgen's?

5 Small-Cap Biotechs In Citi's Buy List With Big Upside Potential

Translate Bio's Novel mRNA Therapy Candidate Addresses A Key Investor Concern, Citi Says

Analysts See Potential In The NuCana Pipeline

Translate Bio's Novel mRNA Therapy Candidate Addresses A Key Investor Concern, Citi Says

|

Analysts See Potential In The NuCana Pipeline

|

A Peek Into The Future For Mirati Therapeutics

|

Citi Says Expect FDA PDUFA Decision For Portola Pharma Early

|

Yigal Nochomovitz Recent News

Puma Biotech 'Is The Real Deal,' Overcomes Controversy With Positive FDA Panel Vote

|

Risk Confirmed: Ultragenyx Shares Downgraded To Sell By Citi

|

7 Binary Trades For The End Of 2016

|

The Street Is Getting The Ophthotech Story All Wrong

|

Here's Why Ophthotech Is Trading Down On Regeneron's News

|

Citi Sees 'Too Much Risk' In Portola Pharma, Downgrades To Neutral

|

Citi Downgrades Mirna Therapeutics To Neutral

|

Buy/High Risk Rating Given To Lexicon Pharmaceuticals By Citi Analysts

|

Galencia's Bid For Relypsa Is 'Reasonable,' Another Bidder 'Unlikely'

|

Medivation's Take-Out Price Raised To $68-$78 At Citi

|

Citi On Medivation-Sanofi Buyout Offer: More Bidders Likely Coming

|

Chimerix Downgraded By Citi's Nochomovitz, Kidney Transplant Play 'Isn't Panning Out'

|

Could Relypsa Be The Next Big Pharma Buyout Target?

|

8 Oppenheimer Analysts Choose Their Favorite Healthcare Stocks

|

Oppenheimer: Own Relypsa (Here's 14 Reasons)

|

UPDATE: Morgan Stanley Downgrades ImmunoGen Following Phase 2 Failure of IMGN901

|